Opinion|Videos|February 12, 2025
BOND-003 Trial and Cretostimogene for Treatment of NMIBC
Author(s)Mark D. Tyson, MD, MPH, Gary D. Steinberg, MD
Panelists discuss how cretostimogene grenadenorepvec is an intravesical oncolytic virus therapy targeting BCG-unresponsive bladder cancer through selective replication in tumor cells and immune stimulation via granulocyte-macrophage colony-stimulating factor expression.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is cretostimogene grenadenorepvec? Please describe its mechanism of action.
- Discuss the phase 3 BOND-003 clinical trial investigating the use of the intravesical immunotherapy cretostimogene grenadenorepvec in patients with high-risk, BCG-unresponsive disease that was recently presented at the Society of Urologic Oncology 2024.
- What are your impressions of the BOND-003 data?
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Interpreting real-world evidence in ARPI treatment decisions, with Martin Schoen, MD, PhD
2
Higher saturated fat intake associated with increased mortality in nonmetastatic prostate cancer
3
NeoBLAST trial tests active surveillance after complete response in MIBC
4
What the Efficacy Data from KEYNOTE-B15/EV-304 Revealed
5